PubRank
Search
About
Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab (T-REX)
Clinical Trial ID NCT01748292
PubWeight™ 0.00
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT01748292
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Ranibizumab for neovascular age-related macular degeneration.
N Engl J Med
2006
30.63
2
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
N Engl J Med
2006
20.84
3
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
N Engl J Med
2011
19.42
4
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
N Engl J Med
1994
16.24
5
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Ophthalmology
2012
11.91
6
A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Am J Ophthalmol
2009
5.41
7
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
Am J Ophthalmol
2008
5.22
8
A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
Ophthalmology
2009
3.76
9
Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.
Ophthalmology
2010
3.22
10
A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact.
Ophthalmology
2010
2.67
11
Ranibizumab according to need: a treatment for age-related macular degeneration.
Am J Ophthalmol
2007
1.54
12
Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration.
Retina
2011
1.28
13
Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
Am J Ophthalmol
2011
1.28
14
"Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
Retina
2009
1.13
Next 100